Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2022 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

AUSTIN, Texas, March 23, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and...
March 22, 2022 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of 186RNL Radiotherapeutic for Leptomeningeal Metastases

ReSPECT-LM trial to evaluate safety/tolerability and identify MTD/MFD in three cohorts Rhenium-186 NanoLiposome (186RNL) now in two active U.S. clinical trials for CNS cancers AUSTIN, Texas, March ...
March 03, 2022 07:30 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Announces Upcoming Participation at the 2022 SNMMI Therapeutics Conference

AUSTIN, Texas, March 03, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted...
February 24, 2022 16:05 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

Expanded pipeline with recently licensed targeted interventional radiotherapeutics platform Announced positive interim data from ReSPECT-GBM Phase 1 clinical trial Management to host conference...
February 22, 2022 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Partners with Medidata to Apply Innovative Synthetic Control ArmⓇ Solution to Accelerate Brain Cancer Clinical Trial

AUSTIN, Texas, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
February 18, 2022 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 24, 2022

AUSTIN, Texas, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
February 07, 2022 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics to Present at BIO CEO & Investor Conference

AUSTIN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
January 07, 2022 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics to Participate in Upcoming January Conferences

AUSTIN, Texas, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
January 06, 2022 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Significantly Expands Investigational Oncology Drug Pipeline

Licenses targeted interventional radiotherapeutics platform Worldwide exclusive rights obtained for patents and next-generation technology to deliver targeted, precision radiotherapeutics for solid...
January 04, 2022 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Announces Two Significant Milestones Toward cGMP Manufacture of its Lead Investigational Radiotherapeutic

IsoTherapeutics Group LLC to develop and supply cGMP grade Rhenium-186 isotope for Plus Therapeutics’ Rhenium-186 NanoLiposome (186RNL) radiotherapeutic Plus Therapeutics completes technology...